Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set
Authors:
- Geoffrey LittlejohnGLGeoffrey Littlejohn
- Paul BirdPBPaul Bird
- Catherine O'SUllivanCOCatherine O'SUllivan
- Opal RheumatologyOROpal Rheumatology
Open Access
- 12 June 2023
- journal article
- research article
- Published by Wiley in ACR Open Rheumatology
- Vol. 5 (7) , 345-353
Abstract
Objective: To analyze comparative treatment persistence for first‐line baricitinib (BARI) versus first‐line tumor necrosis factor inhibitor (TNFi) in patients with rheumatoid arthritis (RA) and for first‐line BARI initiated as monotherapy versus first‐line BARI initiated with at least one conventional synthetic disease‐modifying antirheumatic drug (csDMARD).Methods: Patients with RA who initiated BARI or TNFi as first‐line biologic or targeted synthetic DMARD from October 1, 2015, to September 30, 2021, were identified in the OPAL data set. Drug survival times to 6, 12, and 24 months were analyzed using restricted mean survival time (RMST). Multiple imputation and inverse probability of treatment weighting were used to address missing data and nonrandom treatment assignment.Results: A total of 545 patients initiated first‐line BARI, including 118 as monotherapy and 427 as csDMARD combination therapy. Three thousand five hundred patients initiated first‐line TNFi. There was no difference in drug survival to 6 or 12 months for BARI compared with TNFi; differences in RMST were 0.02 months (95% CI: −0.08 to 0.013; P = 0.65) and 0.31 months (95% CI: −0.02 to 0.63; P = 0.06), respectively. Patients in the BARI group had 1.00 month (95% CI: 0.14 to 1.86; P = 0.02) longer drug survival to 24 months. There was no difference in drug survival for BARI monotherapy compared with combination therapy, with differences in RMST to 6, 12, and 24 months of −0.19 months (95% CI: −0.50 to 0.12; P = 0.12), −0.35 months (95% CI: −1.17 to 0.42; P = 0.41), and −0.56 months (95% CI: −2.66 to 1.54; P = 0.60), respectively.Conclusion: In this comparative analysis, treatment persistence up to 24 months was significantly longer for first‐line BARI compared with TNFi, but the effect size of 1.00 month is not clinically meaningful. There was no difference in persistence for BARI monotherapy versus combination therapy.Keywords
Funding Information
- Eli Lilly and Company
This publication has 22 references indexed in Scilit:
- Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled TrialArthritis & Rheumatology, 2019
- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialThe Lancet, 2017
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug TreatmentArthritis & Rheumatology, 2017
- Baricitinib versus Placebo or Adalimumab in Rheumatoid ArthritisNew England Journal of Medicine, 2017
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD studyAnnals of the Rheumatic Diseases, 2017
- Baricitinib in Patients with Refractory Rheumatoid ArthritisNew England Journal of Medicine, 2016
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studiesStatistics in Medicine, 2015
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomeBMC Medical Research Methodology, 2013
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Multiple Imputation for Nonresponse in Surveys1987